ES2619833T3 - Linaje de células dendríticas plasmacitoides usado en terapia celular activa o adoptiva. - Google Patents
Linaje de células dendríticas plasmacitoides usado en terapia celular activa o adoptiva. Download PDFInfo
- Publication number
- ES2619833T3 ES2619833T3 ES09745821.0T ES09745821T ES2619833T3 ES 2619833 T3 ES2619833 T3 ES 2619833T3 ES 09745821 T ES09745821 T ES 09745821T ES 2619833 T3 ES2619833 T3 ES 2619833T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- pulsed
- pdc
- lineage
- plasmacyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004443 dendritic cell Anatomy 0.000 title description 3
- 238000011467 adoptive cell therapy Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract description 11
- 239000000427 antigen Substances 0.000 abstract description 8
- 108091007433 antigens Proteins 0.000 abstract description 8
- 102000036639 antigens Human genes 0.000 abstract description 8
- 210000004544 dc2 Anatomy 0.000 abstract description 8
- 230000006698 induction Effects 0.000 abstract description 4
- 230000003321 amplification Effects 0.000 abstract description 3
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 3
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 abstract 4
- 108700028369 Alleles Proteins 0.000 abstract 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 230000004044 response Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 239000012979 RPMI medium Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 101100395310 Homo sapiens HLA-A gene Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
Abstract
Procedimiento de inducción y de amplificación in vitro de células inmunitarias capaces de reconocer al menos un antígeno específico, que comprende las etapas siguientes: (a) obtención de un linaje de células dendríticas plasmacitoides (pDC) pulsadas por incubación de un linaje de pDC con dicho al menos un antígeno específico, (b) irradiación de las células obtenidas en la etapa (a), (c) puesta en contacto de pDC pulsadas e irradiadas obtenidas en la etapa (b) con células mononucleadas de sangre periférica (PBMC), y cultivo de las pDC pulsadas e irradiadas y de las PBMC que comparten al menos un alelo del complejo mayor de histocompatibilidad (CMH).
Description
[0059] Para analizar si el linaje de pDC pulsado según la invención permite amplificar una respuesta T específica en pacientes afectados de cáncer, los autores de la invención han cultivado PBMC obtenidas de 5 pacientes HLA-A2 afectados por melanoma en estadio IV con las células GEN2.2 pulsadas con los péptidos derivados de MelA, GP100, MAGE-3 o tirosinasa según el mismo protocolo que en el ejemplo 2. Los linfocitos T CD8+ específicos son analizados por citometría de flujo antes de la estimulación y después de 3 estimulaciones por las células GEN pulsadas (Figura 9a). A continuación se ha evaluado la funcionalidad de los linfocitos T CD8 generados midiendo su actividad citotóxica en los linfocitos T2 pulsados con el péptido de interés o un péptido de
10 control (FluM1) (Figura 9b) según el mismo protocolo que en el ejemplo 4.
[0060] El linaje de pDC GEN2.2 permite así inducir una amplificación masiva de linfocitos T CD8 específicos de diferentes antígenos tumorales a partir de las células de pacientes afectados de cáncer. La actividad citotóxica de los linfocitos T generadas confirma su funcionalidad antitumoral.
[0061] Se ha probado la capacidad de las células GEN2.2 de inducir una respuesta T CD8+ específica de
20 antígeno en situación semialogénica cultivando las células del linaje de pDC pulsado e irradiado en presencia de PBMC de donantes voluntarios sanos HLA-A*0201+. La inducción de una respuesta memoria se evalúa usando el péptido MelanA, la inducción de una respuesta memoria se evalúa con ayuda del péptido flu M1 de la matriz de influenza.
25 [0062] Para pulsar las células GEN2.2 con un péptido de interés, éstas se lavan 3 veces en medio RPMI completo (RPMI 1640 Glutamax suplementado por 1 mM de piruvato de sodio, 20 µg/ml de gentamicina, 100 µM de aminoácidos no esenciales) sin SVF y se vuelven a suspender a 1·106/ml. A las células se les añaden 100 ng/ml de ß2-microglobulina y se incuban 10 min a 37°C (horno). A continuación se añade el péptido de interés a razón de 10 µM (Flu M1) o 1 µM (MelA). A continuación se incuba la suspensión celular 3 h a 37°C (horno) con agitación regular.
30 A continuación se lavan las células, irradiadas a 30 Gy y se vuelven a suspender a 2·105/ml en medio RPMI completo con adición del 10% de suero de ternera fetal. Las PBMC se purifican por Ficoll a partir de bolsas de sangre de donantes sanos. Se vuelven a suspender a 2·106/ml en medio RPMI completo con adición del 10% de suero de ternera fetal. Las células GEN2.2 pulsadas e irradiadas se someten a cocultivo con las PBMC semialogénicas HLA-A2+ en una placa de 24 pocillos (2·105 GEN2.2 + 2·106 PBMC/2 ml) durante 7 a 20 días a
35 37°C. Se llevan a cabo reestimulaciones semanales de los cultivos en el modelo Mel A, en las mismas condiciones que inicialmente, con adición de IL-2 (200 U/ml). Se evalúa el fenotipo de los linfocitos T CD8 al principio de la experimentación (D0) y después de 7 días de cultivo (D7) para la medida de la respuesta anti-FluM1 y después de 7, 14 y 20 días para la medida de la respuesta anti-MelA. La especificidad de los linfocitos T CD8 se analiza gracias a un marcado mediante tetrámeros (Figura 10).
40 [0063] Después de 7 días de cultivo, los porcentajes de linfocitos T tetrámeros+ específicos del antígeno vírico Flu son en promedio del 11% (del 0,1 al 49%) (20 cultivos realizados a partir de las PBMC de donantes diferentes). Los porcentajes de linfocitos T antitumorales dirigidos contra MelA alcanzan en promedio el 22% (del 2 al 60%) después de 20 días de cultivo (18 cultivos realizados a partir de las PBMC de donantes diferentes). Los
45 porcentajes respectivos iniciales de linfocitos T tetrámeros+ anti Flu y anti MelA eran en promedio del 0,23 y el 0,02%.
[0064] Los autores de la invención demuestran en este ejemplo que con esta estrategia es posible que el 100% de los donantes (HLAA* 0201) amplifiquen los linfocitos T específicos de antígenos, en el contexto de una
50 respuesta primaria o memoria.
[0065] Las células del linaje de pDC pulsado e irradiado inducen la amplificación de los linfocitos T
55 específicos HLA-A*0201. Los autores de la invención han evaluado el efecto de la irradiación en la maduración de las pDC, en comparación con las células dendríticas mieloides.
[0066] Se han generado células dendríticas mieloides (MoDC) a partir de monocitos purificados por clasificación negativa (uso del kit EasySep®, según las recomendaciones del fabricante) a partir de PBMC y se han
12
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0802659 | 2008-05-16 | ||
| FR0802659A FR2931163B1 (fr) | 2008-05-16 | 2008-05-16 | Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive |
| PCT/EP2009/055909 WO2009138489A1 (fr) | 2008-05-16 | 2009-05-15 | Lignée de cellules dendritiques plasmacytoïdes utilisée en thérapie cellulaire active ou adoptive |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2619833T3 true ES2619833T3 (es) | 2017-06-27 |
Family
ID=39967489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09745821.0T Active ES2619833T3 (es) | 2008-05-16 | 2009-05-15 | Linaje de células dendríticas plasmacitoides usado en terapia celular activa o adoptiva. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9783782B2 (es) |
| EP (1) | EP2276832B1 (es) |
| CN (1) | CN102165057B (es) |
| AU (1) | AU2009248019B2 (es) |
| CA (1) | CA2724071C (es) |
| DK (1) | DK2276832T3 (es) |
| ES (1) | ES2619833T3 (es) |
| FR (1) | FR2931163B1 (es) |
| WO (1) | WO2009138489A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090061478A1 (en) * | 2006-01-30 | 2009-03-05 | Lene Have Poulsen | High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry |
| EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| EP2167536A1 (en) * | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
| US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
| US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| GB0817244D0 (en) * | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US20110054647A1 (en) * | 2009-08-26 | 2011-03-03 | Nokia Corporation | Network service for an audio interface unit |
| US10250447B2 (en) * | 2014-03-06 | 2019-04-02 | Dell Products, Lp | System and method for providing a U-space aligned KVM/Ethernet management switch/serial aggregator controller |
| IL254565B (en) * | 2015-03-20 | 2022-07-01 | Childrens Nat Medical Ct | Production of t-cells specific for a virus antigen or other antigen from a population of naïve t-cells |
| EP3347028A1 (en) * | 2015-09-10 | 2018-07-18 | Memorial Sloan Kettering Cancer Center | Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy |
| EP3370755B1 (en) | 2015-11-06 | 2021-09-29 | Regents of the University of Minnesota | Activation of resident memory t cells for cancer immunotherapy |
| FR3045386B1 (fr) * | 2015-12-16 | 2018-02-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire |
| CN107266552B (zh) * | 2016-03-30 | 2022-02-08 | 香雪生命科学技术（广东）有限公司 | 源自于prame的肿瘤抗原短肽 |
| WO2018134356A1 (en) * | 2017-01-20 | 2018-07-26 | Etablissement Français Du Sang | Method for predicting the clinical evolution of cancer patients |
| WO2019028406A2 (en) * | 2017-08-03 | 2019-02-07 | Regents Of The University Of Minnesota | ACTIVATION OF LYMPHOCYTES AND MEMORY RESIDENTS FOR THE TREATMENT OF CANCER |
| FR3087448B1 (fr) * | 2018-10-23 | 2023-10-13 | Pdc Line Pharma | Lignee pdc modifiee pour secreter une cytokine |
| CN110684800B (zh) * | 2018-11-02 | 2020-11-03 | 深圳益世康宁生物科技有限公司 | 一种携带肿瘤-睾丸抗原10基因的重组腺相关病毒载体及其应用价值 |
| WO2021027057A1 (zh) * | 2019-08-15 | 2021-02-18 | 成都冕康生物科技有限公司 | 一种针对ebv病毒抗原的b细胞疫苗及其制备方法 |
| CN111077311B (zh) * | 2019-12-30 | 2023-05-09 | 北京立康生命科技有限公司 | 一种酶联免疫斑点检测试剂盒及其检测方法 |
| WO2023217855A1 (en) * | 2022-05-10 | 2023-11-16 | Unikum Therapeutics Aps | Improved cell therapies |
| US20240002800A1 (en) | 2022-05-16 | 2024-01-04 | Mendus B.V. | Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021287A1 (en) * | 1993-03-15 | 1994-09-29 | The Government Of The United States Of America As Represented By The Department Of Health And Human Services | Peptide coated dendritic cells as immunogens |
| DE10139428A1 (de) * | 2001-08-17 | 2003-03-27 | Nemod Immuntherapie Ag | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika |
| FR2848565B1 (fr) * | 2002-12-16 | 2007-04-06 | Ets Francais Du Sang | Lignee de cellules dendritiques gen2.2 |
-
2008
- 2008-05-16 FR FR0802659A patent/FR2931163B1/fr active Active
-
2009
- 2009-05-15 CA CA2724071A patent/CA2724071C/fr active Active
- 2009-05-15 AU AU2009248019A patent/AU2009248019B2/en active Active
- 2009-05-15 ES ES09745821.0T patent/ES2619833T3/es active Active
- 2009-05-15 DK DK09745821.0T patent/DK2276832T3/da active
- 2009-05-15 CN CN200980117458.2A patent/CN102165057B/zh active Active
- 2009-05-15 WO PCT/EP2009/055909 patent/WO2009138489A1/fr active Application Filing
- 2009-05-15 EP EP09745821.0A patent/EP2276832B1/fr active Active
- 2009-05-15 US US12/993,076 patent/US9783782B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2276832T3 (da) | 2017-03-13 |
| CA2724071C (fr) | 2020-03-31 |
| CN102165057B (zh) | 2015-07-29 |
| US9783782B2 (en) | 2017-10-10 |
| AU2009248019A1 (en) | 2009-11-19 |
| CN102165057A (zh) | 2011-08-24 |
| FR2931163A1 (fr) | 2009-11-20 |
| CA2724071A1 (fr) | 2009-11-19 |
| EP2276832B1 (fr) | 2016-12-21 |
| AU2009248019B2 (en) | 2014-04-17 |
| FR2931163B1 (fr) | 2013-01-18 |
| WO2009138489A1 (fr) | 2009-11-19 |
| US20120020998A1 (en) | 2012-01-26 |
| EP2276832A1 (fr) | 2011-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2619833T3 (es) | Linaje de células dendríticas plasmacitoides usado en terapia celular activa o adoptiva. | |
| ES2647533T3 (es) | Diferenciación de células madre pluripotentes de primate a células de linaje hematopoyéticas | |
| Anguille et al. | Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties | |
| ES2391573T3 (es) | Método para el tratamiento de activación de una célula presentadora de antígeno | |
| Moser et al. | Optimization of a dendritic cell-based assay for the in vitro priming of naive human CD4+ T cells | |
| EP2459707B1 (en) | Compositions and methods of preparing alloreactive cytotoxic t cells | |
| US20170196910A1 (en) | Gamma delta t cells and uses thereof | |
| KR20170067751A (ko) | 저산소 및 정상산소 교대 조건에서 골수 침윤성 림프구의 활성화 | |
| ATE476497T1 (de) | Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie | |
| JP6987338B2 (ja) | ＭＨＣＩＩ拘束性ＣＤ４＋ＦＯＸＰ３＋制御性Ｔ細胞のｅｘ ｖｉｖｏ生成及びその治療的使用 | |
| KR20180054523A (ko) | 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물 | |
| US20210238550A1 (en) | METHOD FOR PRODUCING REGENERATED T CELL POPULATION VIA iPS CELLS | |
| CA2807892A1 (en) | Compositions and methods for producing dendritic cells | |
| CN107002035A (zh) | 干细胞组合物和生产用于治疗应用的干细胞的方法 | |
| Hansen et al. | Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21 | |
| Aspord et al. | Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases | |
| Berk et al. | Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs | |
| CA2640836C (en) | Method for generating dendritic cells employing decreased temperature | |
| de Lastic et al. | Effect of dendritic cell state and antigen-presentation conditions on resulting T-cell phenotypes and Th cytokine profiles | |
| WO2020251046A1 (ja) | 医薬組成物 | |
| JPWO2017188033A1 (ja) | 効率的なｎｋｔ細胞活性化技術 | |
| Krishnadas et al. | Wilms’ tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood | |
| Bulgarelli et al. | Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone | |
| US20240131079A1 (en) | Extracellular vesicles derived from induced pluripotent and embryonic stem cells, and methods of use for immune modulation | |
| US20240117310A1 (en) | Human Cross-Presenting CD141+CLEC9A+ Dendritic Cells, Methods of Producing the Same from Mobilized Peripheral Blood CD34+ Hematopoietic Stem Cells and Methods of Use |